Comparison
Retatrutide vs. TB-500
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Healing
CAS no.
2381089-83-2
no data
Molecular weight
4731.6 g/mol
888 g/mol
Half-life
144 h
no data
Sequence
Y-Aib-EGTFTSDYSIYLDKQAAQDFVQWLLDTGPSSGAPPPSAc-LKKTETQMechanism of action
Retatrutide
Retatrutide is a 39-amino-acid peptide with agonism at three incretin/energy-balance receptors: GLP-1R (insulin secretion, satiety), GIPR (insulin sensitivity, lipid metabolism) and the glucagon receptor (energy expenditure, lipolysis). The added glucagon activation is intended to raise catabolic energy expenditure while concurrent GLP-1/GIP action compensates the hyperglycaemic effect. Albumin binding via a fatty-acid side chain enables weekly dosing.
TB-500
Synthetic fragment of the endogenous protein Thymosin Beta-4. In preclinical models, an influence on cell migration, actin sequestration and neovascularisation has been described. Robust human pharmacokinetic data are not publicly available.
Evidence base
Highest evidence
Human RCT
Animal model
Studies
5
3
of which in humans
4
0
Effects recorded
4
4
Open conflicts
0
1
Documented adverse events
2
2